1. Home
  2. Research Topics
  3. Immunology
  4. Human IL-8 ELISA

Human IL-8 ELISA

The IL-8 ELISA is to be used for the in-vitro quantitative determination of interleukin-8. (IL-8) in human serum, plasma, buffered solutions or cell culture medium.


Species: Human
Catalog No Size
Product Catalog No: 950.050.192 Pack Size: 2 x 96

Pack Size:
Pack Size:
Pack Size:
Pack Size:

Category:
Summary

Interleukin 8 (IL-8) or CXCL8, Monocyte-Derived Neutrophil Chemotactic Factor (MDNCF), Neutrophil Activating Factor (NAF), NAD-P1 is a chemokine secreted by monocytes, macrophages and endothelial cells. IL-8 chemoattracts and activates neutrophils

The predominant form of IL-8 is a 8.4kDa protein containing 72 amino acid residues, which includes five additional N-Terminal amino-acids. IL-8 contains the four conserved cysteine residues present in CXC chemokines and also contains the “ELR” motif common to CXC chemokines that binds to CXCR1 and CXCR2.

Data indicate that IL-8 may participate in the pathogenesis of rheumatoid arthritis (5) via the induction of neutrophil-mediated cartilage damage (6), and psoriasis(7).A causative involvement of IL-8 is found within a broad range of clinico-pathological conditions : adult respiratory distress syndrome, asthma, bacterial infections, bladder cancer, graft rejection, influenza virus infection…Due to the nowdays known biological properties of IL-8, this cytokine especially in combinations with other neutrophil activating agents, may prove helpful in the treatment of patients suffering from granulocytopenia, severe infections against which antibiotics are not effective, and immunodeficiency caused by HI-virus.

Test Principle

A monoclonal antibody specific for IL-8 has been coated onto the wells of the microtiter strips provided.

During the first incubation, IL-8 present in the sample or standard and a polyclonal anti IL-8 antibody conjugated to biotin are simultaneaously incubated.

Following incubation unbound biotinylated anti-IL-8 is removed during a wash step.

Streptavidin-HRP is added and binds to the biotinylated anti IL-8. After incubation and a wash step a substrate solution reactive with HRP is added to the wells.

A coloured product is formed in proportion to the amount of IL-8 present in the sample. The reaction is terminated by addition of acid and absorbance is measured at 450 nm.

References
  1. Gombocz, K. et al., Crit Care,2007; 11(4): R87
  2. Gironella J. et al., Gut, 2005; 54(9): 1244 – 1253
  3. Eilertsen, G. O. et al., Lupus,2011 ; 20(6): 607-613.
  4. Rybka, J. et al.,Clin Exp Med.,2015; 16(4): 493-502.
  5. Akbari, F. et al., Iran J Neurol.,2016; 15(2): 75-9.
  6. Chabbert-de Ponnat, I. et al., Int Immunol.,2005; 17(4): 439-47.
  7. Gehrke, T. et al., Oncol Lett.,2016; 12(5): 3549-3554
  8. Giamarellos-Bourboulis, E. J. et al., Crit Care,2006; 10(3): R76
  9. Kumpf, O. et al. ,Crit Care,2010; 14(3): R103.
  10. Lekkou A. et al., Clin. Diagn.Lab. Immunol., 2004; 11(1):161 – 167
  11. Rajappa, M. et al., Angiology,2009; 60(4): 419-426.
  12. Rana, S. V. et al., J Crohns Colitis,2014 ; 8(8): 859-865
  13. Routsi, C. et al.,Clin Exp Immunol.,2005;142(1): 62-7.
  14. Sell, H. et al., Am J Physiol Endocrinol Metab., 2008;294:E1070-E1077
  15. Tsaganos, T. et al.,BMC Infect Dis.,2006; 6: 142.
  16. Yadav, U. C. S. et al., J. Immunol.,2009; 183(7): 4723-4732.
  17. Audibert, C. et al., Infect Immun., 2001; 69(3): 1625-9.
  18. Bäcked F. et al., J. Biol. Chem., 2002; 277(20): 18198 – 19205
  19. Backhed, F. et al., Infect Immun., 2003; 71(6): 3357-60.
  20. Bellanger, A.-P. et al.,Clin. Vaccine Immunol., 2013 ; 20(8): 1133-1142.
  21. Bonnans, C. et al., Am J Pathol.,2006;168(4):1064-72.
  22. Bote, M. E. et al.,PLoS One,2013 ; 8(9): e74524
  23. Chavushyan, A. et al., Schizophr Res Treatment,2013: 125264
  24. Coconnier, M. H. et al., Appl Environ Microbiol.,2000; 66(3): 1152-7.
  25. Eleftheriadis, T. et al.,Hippokratia,2011;15(3): 238-43
  26. Ellmerich S. et al., Carcinogenesis, 2000; 21(4): 753 -756
  27. Fan, H. et al., Mol Immunol.,2007; 44(12): 3092-9
  28. Guerrero, A. et al.,Aging Cell,2015 ; 14(2): 274-83
  29. Hot, A. et al., Ann Rheum Dis, 2012; 71: 768 – 776.
  30. Krishna, S. et al., PLoS One,2011; 6(12): e28476
  31. Krzysiek, R. et al., J Immunol.,1999;162(8): 4455-63
  32. Lee, H. W. et al.,Ann Dermatol.,2013 ; 25(2): 173-80
  33. Levy, B. D. et al., Prostaglandins Leukot Essent Fatty Acids,2011; 84(1-2): 43-50.
  34. Maruyama, H. et al.,Lipids Health Dis.,2014; 13: 78
  35. Mazurkiewicz, P. et al.,Mol Microbiol.,2008; 67(6): 1371-83.
  36. Roy, S. et al.,Immunology,2004; 112(3): 471-80.
  37. Saraiva M. et al., JEM 2002; 196(6): 829-839
  38. Sjolinder,H et al., Infect Immun., 2008; 76(9)3959-66
  39. Tenca C. et al., 2005; 174(11): 6757 – 6763
  40. Toutirais, O. et al., Clin Exp Immunol.,2007; 149(2): 372-7
  41. Tutar, E. et al., World J Gastroenterol.,2008;14(20): 3218-23.
  42. van de Sande, W.W.J. et al., J. Immunol.,2007; 179(5): 3065-3074.
  43. Vassallo, R. et al.,Mol Immunol.,2008; 45(12): 3321-9.
  44. Yadav, U. C. et al.,PLoS One,2009; 4(8): e6535
  45. Zrioual, S. et al., J. Immunol.,2008; 180(1): 655-663.
  46. Zhang, J. et al.,Tanaffos. 2017 Jun;16(4):260-269.
  47. Jaswal, S. et al.,Int J Appl Basic Med Res. 2018 Jan-Mar;8(1):14-18.
  48. Hurtado, J.A. et al.,Breastfeed Med. 2017 May 1; 12(4): 202–209.
Order Enquiry

    Order Enquiry Form

    Documents
    Enquiry